Change search
ReferencesLink to record
Permanent link

Direct link
Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
Show others and affiliations
2014 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 74, no 3, 549-558 p.Article in journal (Refereed) Published
Abstract [en]

Use of the patient's body surface area (mg m(-2)) as a basis for dosing does not take individual variation in metabolic capacity and rate of clearance into account. Here, we evaluated a novel approach for individual monitoring of short-lived cytotoxic agents formed from cytostatic drugs such as cyclophosphamide (CP). The accumulated blood dose of the cytotoxic active agent phosphoramide mustard (PAM) formed from CP was measured as a reaction product with hemoglobin (Hb adduct). This adduct, N-[2-(2-oxazolidonyl)ethyl]-valyl Hb (OzVal-Hb), was detached from Hb with the adduct FIRE procedure (TM), and the formed analyte was quantified using LC-MS/MS. This dose biomarker for PAM and the analytical procedure was evaluated in accordance with the guidelines on bioanalytical method validation formulated by the European Medicine Agency. The evaluated method was applied to quantify blood dose levels of PAM in female breast cancer patients (n = 12) before and after three cycles of polychemotherapy regimes containing CP. OzVal-Hb, a specific and stable biomarker, could be measured with great sensitivity (lower limit of quantification = 33 pmol g(-1) Hb), high accuracy (within +/- 20 %) and good repeatability (CV < 20 %). The inter-individual variability in the blood level of this adduct in women with breast cancer (n = 12) who received three doses of CP in combination with one or two other cytostatic drugs was 250 % following the first dose and approximately 150 % after each subsequent dose. Measurement of the biomarker OzVal-Hb can be used to quantify the short-lived cytotoxic agent PAM in a single blood sample drawn several days after therapy. This procedure may aid in individualizing doses of CP, thereby improving efficacy while both reducing the risk of and increasing the predictability of side-effects.

Place, publisher, year, edition, pages
2014. Vol. 74, no 3, 549-558 p.
Keyword [en]
Cyclophosphamide, Phosphoramide mustard, Personalized cancer medicine, Hemoglobin adducts, Therapeutic drug monitoring, TDM
National Category
Cancer and Oncology Chemical Sciences
URN: urn:nbn:se:su:diva-107794DOI: 10.1007/s00280-014-2524-7ISI: 000341180200014OAI: diva2:753017


Available from: 2014-10-06 Created: 2014-09-29 Last updated: 2014-10-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Rydén, Andreas
By organisation
Department of Materials and Environmental Chemistry (MMK)
In the same journal
Cancer Chemotherapy and Pharmacology
Cancer and OncologyChemical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 24 hits
ReferencesLink to record
Permanent link

Direct link